Company Overview
Electromed, Inc. operates within the healthcare sector specifically focusing on the medical devices industry, where it develops, manufactures, markets, and sells airway clearance therapy and related products utilizing high frequency chest wall oscillation (HFCWO) for pulmonary care in the United States and internationally. The company's primary offering includes the SmartVest airway clearance system, which is designed to assist patients with respiratory conditions through targeted therapy applications. This entity currently maintains a market capitalization of $205.68M and generates annual revenue of $68.86M over a trailing twelve-month period, supported by a workforce of 177 employees. The valuation figure of $205.68M indicates a mid-cap positioning within the specialized medical device space, while the revenue of $68.86M suggests an established operational footprint capable of sustaining a dedicated team of 177 employees without requiring the massive capitalization typically associated with broad-market pharmaceutical or biotechnology peers.
Financial Health
Over the trailing twelve months, the company reported revenue of $68.86M, net income of $8.99M, and EBITDA of $12.88M, illustrating a cost structure where operating expenses and taxes consume a significant portion of top-line growth before reaching the bottom line. The difference between the $68.86M revenue and the $8.99M net income reveals an operating environment with substantial fixed costs and tax obligations that result in a profit margin of 13.1%, while the $12.88M EBITDA highlights the underlying cash earnings power before interest and non-cash expenses. The business generated $7.08M in free cash flow, which provides the financial flexibility to fund operations, invest in product development, or manage liquidity without relying heavily on external financing. Profitability analysis shows a gross margin of 78.2%, indicating highly efficient production and pricing power typical of specialized medical device manufacturing, alongside an operating margin of 19.2% that reflects the scale of overhead relative to sales. The balance sheet demonstrates a conservative stance with $13.79M in cash holdings against only $96,000 in debt, supported by a low debt-to-equity ratio of 0.21 that minimizes financial risk. Liquidity is robust as evidenced by a current ratio of 4.86, meaning the company holds nearly five times more current assets than current liabilities, ensuring ample capacity to meet short-term obligations. Management effectiveness is quantified by a return on equity of 20.2% and a return on assets of 13.6%, metrics that demonstrate the ability to generate substantial returns relative to the capital invested and the total asset base employed.
Valuation Assessment
The stock carries a trailing P/E ratio of 23.94 compared to a forward P/E of 40.43, implying that the market is pricing in a significant anticipated increase in earnings or that current earnings are being suppressed by one-time costs, resulting in a higher valuation multiple for future performance. The price-to-book ratio stands at 4.49, suggesting the market assigns a substantial premium to the company's intangible assets, brand value, and proprietary technology beyond the net asset value recorded on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 2.99 and an EV/EBITDA of 14.78, which together suggest the company is valued at nearly three times its annual sales and approximately 15 times its adjusted earnings before interest, taxes, depreciation, and amortization. Price action within the last year has oscillated between a 52-week high of $30.73 and a 52-week low of $17.73, placing the current trading price within this historical range and reflecting recent market sentiment fluctuations. The stock exhibits a beta of 0.31, indicating that its price volatility is significantly lower than the broader market, as it tends to move with only about one-third of the magnitude of market swings.
Growth & Income
Revenue growth year-over-year stands at 16.3%, while earnings growth year-over-year is reported at 45.5%, indicating that earnings are expanding at a rate substantially faster than revenue, which implies improving operational efficiency or pricing leverage rather than just top-line volume expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all net income to reinvest into growth initiatives, research, and development of its airway clearance systems. This retention strategy aligns with the company's profile as a growth-oriented medical device manufacturer that prioritizes capital allocation toward expanding market share and technological innovation over distributing cash to shareholders. The overall growth and income profile is characterized by strong double-digit earnings acceleration and a complete reinvestment of profits to fuel future expansion within the pulmonary care sector.